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Abstract
Background—Phenylacetic acid (PAA) is the active moiety in sodium phenylbutyrate (NaPBA)
and glycerol phenylbutyrate (GPB, HPN-100), both are approved for treatment of urea cycle
disorders (UCDs) - rare genetic disorders characterized by hyperammonemia. PAA is conjugated
with glutamine in the liver to form phenylacetyleglutamine (PAGN), which is excreted in urine.
PAA plasma levels ≥500 μg/dL have been reported to be associated with reversible neurological
adverse events (AEs) in cancer patients receiving PAA intravenously. Therefore, we have
investigated the relationship between PAA levels and neurological AEs in patients treated with
these PAA pro-drugs as well as approaches to identifying patients most likely to experience high
PAA levels.
Methods—The relationship between nervous system AEs, PAA levels and the ratio of plasma
PAA to PAGN were examined in 4683 blood samples taken serially from: [1] healthy adults [2],
UCD patients ≥2 months of age, and [3] patients with cirrhosis and hepatic encephalopathy (HE).
The plasma ratio of PAA to PAGN was analyzed with respect to its utility in identifying patients
at risk of high PAA values.
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Results—Only 0.2% (11) of 4683 samples exceeded 500 ug/ml. There was no relationship
between neurological AEs and PAA levels in UCD or HE patients, but transient AEs including
headache and nausea that correlated with PAA levels were observed in healthy adults. Irrespective
of population, a curvilinear relationship was observed between PAA levels and the plasma
PAA:PAGN ratio, and a ratio > 2.5 (both in μg/mL) in a random blood draw identified patients at
risk for PAA levels > 500 μg/ml.
Conclusions—The presence of a relationship between PAA levels and reversible AEs in healthy
adults but not in UCD or HE patients may reflect intrinsic differences among the populations
and/or metabolic adaptation with continued dosing. The plasma PAA:PAGN ratio is a functional
measure of the rate of PAA metabolism and represents a useful dosing biomarker.
Keywords
BUPHENYL; glycerol phenylbutyrate; HPN-100; neurological adverse events; pharmacokinetics;
RAVICTI; sodium phenylbutyrate
INTRODUCTION
Glycerol phenylbutyrate, a sodium- and sugar-free phenylbutyrate derivative, and sodium
phenylbutyrate are approved as ammonia lowering agents in patients with urea cycle
disorders (UCDs). Both are pro-drugs of phenylacetic acid (PAA), which is formed by beta-
oxidation from phenylbutyric acid (PBA) delivered either as glycerol phenylbutyrate
following its intestinal hydrolysis by pancreatic lipases [1] or as sodium phenylbutyrate
following dissociation in the stomach. PAA is conjugated with glutamine by glutamine-N-
phenylacetyltransferase, largely in the liver and to a lesser extent in the kidney [2], to form
phenylacetylglutamine (PAGN), which is excreted in urine, thereby providing an alternate
pathway to urea for waste nitrogen excretion. In controlled studies population
pharmacokinetic analyses of sodium phenylbutyrate and glycerol phenylbutyrate, it has been
shown that the gastrointestinal absorption of PBA is approximately 75% slower when
delivered as glycerol phenylbutyrate vs. sodium phenylbutyrate and that plasma PAA and
PAGN levels show less variability during glycerol phenylbutyrate dosing. [3]-[7]. There are
over 30 reports of the administration of sodium phenylacetate or sodium phenylbutyrate to
healthy volunteers, patients with UCDs or other metabolic disorders and patients with
cancer, many of which reported some adverse events (AEs) attributed to PAA
(Supplemental Table 1) [8]-[36]. These reversible AEs in cancer patients were reported in
studies involving continuous or intermittent intravenous administration designed to maintain
high levels of PAA, suggesting that duration of exposure as well as peak PAA levels are
important [35],[3].
The AEs reportedly associated with high levels of PAA have most commonly included
nausea, headache, emesis, fatigue, weakness, lethargy, somnolence, dizziness, slurred
speech, memory loss, confusion, and disorientation [35], [36]. Except for the symptoms of
Kussmaul respiration, metabolic acidosis, cerebral edema, and coma associated with a fatal
overdose of sodium phenylacetate/sodium benzoate (AMMONUL®)[13], the symptoms
were rapidly reversible with reduced dosing or interruption of dosing.
Mokhtarani et al. Page 3
Mol Genet Metab. Author manuscript; available in PMC 2014 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Based on a detailed analysis of the timing of the AEs in relation to blood PAA
concentrations, Simell calculated the safe upper PAA concentration limit to be 3.5 mmol/L,
equivalent to 476 μg/mL [22], and Thibault reported that AEs were associated with PAA
levels ranging from 499–1285 μg/mL [35], [36] .
Sodium phenylbutyrate (BUPHENYL®) has been used for over three decades in the
treatment of UCDs. Despite the fact that the AEs reportedly associated with elevated plasma
PAA levels can mimic those associated with hyperammonemia, little is known regarding the
relationship between PAA levels and AEs in UCD patients. The clinical trials of glycerol
phenylbutyrate (RAVICTI®, HPN-100), which included over 100 UCD patients, 80 of
whom underwent comparative study of sodium phenylbutyrate and glycerol phenylbutyrate
[3] - [6] (the largest prospectively studied group of patients with this rare disorder), 193
patients with advanced cirrhosis complicated by hepatic encephalopathy (HE) [37], and
more than 90 healthy adult subjects have afforded a unique dataset and opportunity to
systematically examine the relationship between PAA levels and AEs and to explore
biomarkers indicative of patients most likely to experience elevated PAA levels.
METHODS
Clinical Studies (Table 1)
Data from a thorough QTc study in healthy adults, five clinical studies in UCD patients and
an open label safety and dose escalation study as well as a randomized, double-blinded
controlled phase 2 study of patients with decompensated cirrhosis complicated by HE
formed the basis for these analyses.
UCD Patients
Eighty UCD patients completed 4 short-term (10 to 28 days) cross-over studies of sodium
phenylbutyrate vs. glycerol phenylbutyrate (Table 1). The short-term UCD study population
included 26 pediatric patients ages ≥2 mos through 17 years who received a mean (range)
dose of 8 (1-19) g/day of glycerol phenylbutyrate or an equivalent dose of sodium
phenylbutyrate and 54 adults patients ages 18 years or older who received a mean (range)
dose of 13 (2-34) g/day of glycerol phenylbutyrate or an equivalent dose of sodium
phenylbutyrate [3] [4] [5][6]. In addition, data from 100 UCD patients enrolled in 12-month
glycerol phenylbutyrate treatment protocols including 49 children and 51 adults were
analyzed in relation to PAA levels over time and the occurrence of the symptoms reported in
cancer patients by Thibault [35][36][4] [5][6] during 12 months treatment.
Patients with Cirrhosis and HE
Data from a 4-week safety and dose escalation study and a multicenter, randomized placebo-
controlled study of 178 patients with cirrhosis and hepatic encephalopathy who received
13.2 g/day of glycerol phenylbutyrate (N=90) or placebo (N=88) for 16 weeks were
analyzed [37], [38] (Table 1). Patients were monitored for safety and frequent PK samples
were taken over the course of the study.
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Healthy Adults
A total of 98 healthy adults (mean age of 28; 53 male 45 female) participated in a blinded,
randomized, cross over study to assess effects of glycerol phenylbutyrate and its metabolites
on QTc and other ECG parameters (Table 1). In this protocol 12 subjects received 29.7 g/
day, 4 subjects 39.6 g/day of glycerol phenylbutyrate and 68 subjects received placebo,
moxifloxacin as the positive control and glycerol phenylbutyrate at doses of 13.2 g/day and
19.8 g/day administered three times daily for 3 days.
Adverse Event Mapping
All treatment emergent adverse events (AEs) coded as to Body System as Nervous System
Disorders using the Medical Dictionary for Regulatory Activities (MedDRA) in subjects
enrolled in these studies were included in the analyses. For UCD patients, the specific
toxicities reported by Thibault [35], [36], including nausea, headache, emesis, fatigue,
weakness, lethargy, somnolence, dizziness, slurred speech, memory loss, confusion, and
disorientation, exacerbation of neuropathy, pedal edema, hearing loss, abnormal taste,
arrhythmia, rash, Kussmaul respiration, metabolic acidosis, increased anion gap, tachypnea,
abdominal discomfort, cerebral edema, and obtundation or coma, were mapped to the
MedDRA preferred terms in the clinical trial databases.
Analysis of AEs in Relation to PAA Levels
Analyses were based on (a) 2126 samples from 98 healthy adults, (b) 1281 blood PAA and
PAGN values derived from 80 UCD patients during the short term-switchover studies who
received both sodium phenylbutyrate and glycerol phenylbutyrate, and (c) 428 samples from
90 patients with cirrhosis and HE who received glycerol phenylbutyrate. Because plasma
PAA levels were not always available at the time the patient was experiencing an AE, the
following rules were applied to associate an AE to a known PAA level. For healthy subjects,
maximum PAA values recorded after the first dose but within 24 hours of the last dose and
the incidence of neurological AEs (yes/no) were summarized by dosing period; for periods
where subjects received placebo or moxifloxacin, the PAA levels were set to 0. For UCD
patients, maximum PAA values (Cmax) recorded during each dosing period and the
incidence of neurological AEs were summarized by treatment (glycerol phenylbutyrate or
sodium phenylbutyrate). For HE patients, each AE was attributed to the PAA result that was
closest in time to the AE.
The contribution of a 20 μg/mL increase in PAA levels to the probability of a neurological
AE regardless of relationship to the study drug was examined using Generalized Estimating
Equations [39]. For healthy subjects, data were summarized for each dose group. Since
UCD patients received a range of doses, data were summarized for patients receiving a dose
greater or less than the median dose (equivalent to 11.7 g/day). For HE patients,
neurological AEs were examined both in relation to blinded treatment group assignment; i.e.
glycerol phenylbutyrate or placebo, as well as in relation to PAA levels among patients
treated with glycerol phenylbutyrate.
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Analysis of PAA in Relation to Plasma PAA:PAGN Ratio
GEE were used to model the predictive value of plasma PAA:PAGN ratio in identifying
patients at risk of a high plasma PAA level as defined to have a PAA level equal or greater
than 400 μg/mL or 500 μg/mL during 24 hours of dosing . Plasma PAA:PAGN ratios were
grouped into binary categorical range of less than 2.5 or greater than 2.5. The repeated
measures categorical outcome was modeled using GEE with a logit link function, ratio
category as the independent variable, and the individual subject ID as the repeated measures
factor. Confidence intervals for the predicted probabilities were computed by bootstrap
estimation of 1000 re-samplings of the original data, as detailed in Davison and Hinkley
[40].
RESULTS
UCD patients (Table 2, Figure 1)
Common AEs reported by at least 10% of patients during short-term treatment with either
drug included diarrhea, flatulence, and headache. Neurological AEs reported by more than 1
UCD patient included headache, dizziness and dysgeusia. The mean (SD) PAA Cmax was
similar in patients who reported at least one neurological AE, as compared with those who
did not (50.8 (34.5) μg/mL vs 51.5 (49.23) μg/mL respectively). There was no statistically
significant relationship in UCD patients between the presence or absence of neurological
AEs and PAA levels during either glycerol phenylbutyrate or sodium phenylbutyrate
treatment. The odds ratio of a neurological AE occurring for each 20 μg/mL increase in
PAA levels for the two drugs combined, controlling for dose level, was 0.929, very close to
1 indicating that increasing levels of PAA were not associated with an increase in
neurological AEs in these studies. There was no difference in the frequency of the PAA-
associated AEs reported in cancer patients by Thibault [35], [36] in adult vs. pediatric UCD
patients in the short-term controlled studies, despite the generally higher PAA levels in
pediatric patients (Supplemental Table 2).
A total of 100 UCD patients enrolled in 12-month studies of glycerol phenylbutyrate
received a mean (SD) total dose of 11.01 (5.970) g/day (range: 0.8–34.3 g). Overall common
AEs reported in at least 10% of UCD patients during long-term treatment included vomiting,
upper respiratory tract infection, nausea, nasopharyngitis, diarrhea, headache,
hyperammonemia, decreased appetite, cough, fatigue, dizziness, and oropharyngeal pain.
There was no increase either in plasma PAA levels (Supplemental Figure 1) or the rate of
AEs over time. Just as in the short-term studies there was no difference between pediatric
and adult patients in the frequency of the PAA-associated AEs reported in cancer patients by
Thibault (Supplemental Table 2).
Patients with cirrhosis and HE (Table 2, Figure 1)
Of 88 patients randomized to placebo, 48.9% reported a neurological AE as compared to
40.9% of 90 patients randomized to glycerol phenylbutyrate. Of the 428 PAA data points
from patients randomized to glycerol phenylbutyrate, 46 were in patients who reported a
neurological AE and 382 in patients who did not. The mean (SD) PAA value closest to
occurrence of an AE was 61.4 (75.3) μg/mL while the mean PAA value not temporally
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associated with an AE was 36.4 (55.6) μg/mL (p=0.77) (Figure 2). Similar to UCD patients,
there was no increase in the odds of experiencing a neurological AE with each 20 μg/mL
increment in PAA levels in cirrhosis patients (odds ratio 1.086; p=0.172) indicating that at
the dose of 13.2 g/day the odds of experiencing a neurological AE did not increase with an
increase in PAA level.
Healthy subjects
Common AEs in ≥ 10% of healthy volunteers included headache, nausea, and dizziness.
Neurological AEs increased in frequency with increasing dose, ranging from 26.5% for 13.2
g/day to 91.7% for 29.7 g/day. Among those who reported a neurological AE, PAA values
were higher for the 19.8 g/day, 29.7 g/day, and 39.6 g/day dosing periods than for the 13.2
g/day dosing period (Figure 2, Table 2). PAA levels increased as the dose of glycerol
phenylbutyrate increased. In the case of the 13.2 g/day dose group, the difference was
statistically significant (73.3 vs. 41.6, p <0.001) (Table 2). Logistic regression analysis
indicated that each increment in PAA of 20 μg/mL was associated with increasing odds of
experiencing a neurological AE (odds ratio = 1.75; p = 0.006). Individual AEs reported by
healthy adults were generally transient and typically began within 36 hours of dosing and
generally resolved with continued dosing, as depicted in Supplemental Figure 2.
Plasma PAA:PAGN ratio as a Predictor of Elevated PAA Levels
PAA levels showed considerable variation over a 24-hr period in all patients regardless of
the dose, drug and population (Figure 3). Unlike PAA, the ratio of PAA:PAGN was
comparatively constant over 24 hours (data not shown). A curvilinear relationship was
observed between PAA and PAA:PAGN in all populations, with a sharp upward inflexion
beginning with PAA concentrations approaching 200 μg/ml and a PAA:PAGN of
approximately 2.5 or greater (Figure 4). Only 11 of a total of 4683 samples exceeded the
500 ug/ml threshold level reported by Thibault to be associated with occurrence of
neurological AEs in cancer patients. The estimated probabilities of correctly detecting a ratio
≥2.0 based on a single plasma sample taken at any time between the fasting morning sample
(0 hr time point) and early evening (12 hr time point) remained relatively constant (77% to
84%), indicating that the timing of blood draw did not have an impact on the ratio of
PAA:PAGN in plasma regardless of the PAA concentration. Patients with a ratio ≥2.5 had
significantly higher PAA levels than those with a ratio ≤2.5 (p<0.0001) and PAA:PAGN
ratios ≥2.5 had an approximately 20 times higher probability of being associated with PAA
levels > 400 μg/ml (0.8% vs. 19.1%) or 500 μg/ml (0.3% vs. 8.4%) (Table 3).
DISCUSSION
No relationship was observed among UCD patients between PAA levels and either
neurological AEs, or the specific AEs reported by Thibault, during treatment with either
glycerol phenylbutyrate or sodium phenylbutyrate. This is supported by (a) the absence of a
relationship during short term treatment in UCD patients, in which the odds ratio for the
likelihood of a neurological AE for every 20 μg/mL increase in PAA levels was 0.929, (b)
the absence of a difference in the frequency of AEs similar to those reported in cancer
patients by Thibault between pediatric and adult UCD patients during short or long-term
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treatment, despite generally higher PAA levels in pediatric patients, and (c) the absence of
any change in either PAA levels or the pattern of AEs during 12 months of dosing.
Similarly, no statistical relationship was noted between PAA levels and neurological AEs
among HE patients treated with 13.2g/day of glycerol phenylbutyrate for 16 weeks, as there
was no difference in neurological AEs between the glycerol phenylbutyrate and placebo
treatment arms, nor was there a relationship between PAA levels and the occurrence of
neurological AEs.
Among the healthy adult volunteers, a relationship was observed between PAA levels and
the occurrence of any neurological AE (e.g. headache, dizziness, vomiting and nausea).
These AEs were generally mild, started early in the dosing period, and disappeared with
continued dosing. The theoretical risk of PAA toxicity is expected to be similar for sodium
phenylbutyrate or glycerol phenylbutyrate, as both drugs convert to PAA upon absorption.
The AEs reported by healthy volunteers in these studies receiving glycerol phenylbutyrate
are generally consistent with prior reports involving administration of sodium
phenylbutyrate. The mechanism for these AEs is unknown, although interference with brain
biochemical function has been suggested [41]. These differences between populations may
be attributable either to metabolic differences between UCD and HE patients, who exhibit
pathological nitrogen retention and high glutamine levels, as compared with healthy adults,
and/or metabolic adaptation that may occur with continued exposure to PAA in chronically
treated patients. Consistent with adaptation are the findings that AEs tended to disappear
with continued dosing in healthy adults and that the UCD patients enrolled in these studies
had been treated with sodium phenylbutyrate for an average of more than 9 years.
While most human tissues are capable of beta-oxidation and, hence, conversion of
phenylbutyrate to PAA [42], enzymatic conversion of PAA to PAGN occurs primarily in the
liver [2]. This may explain why conversion of PAA to PAGN appears to be a rate-limiting
step in the metabolism of PAA prodrugs and why PAA metabolism may be compromised
when liver function is poor, when availability of the precursor glutamine may be limited as
in healthy subjects, and/or when the capacity of the enzymatic conversion may be limited as
in very young children [7]. Regardless of the reason, decreases in the rate of PAGN
formation are associated with an increased ratio of PAA to PAGN in plasma. It is interesting
in this regard that the upward inflexion in PAA values assessed as a function of the
PAA:PAGN ratio occurs at a concentration similar to the estimated Km of this reaction
based on population PK modeling, which is approximately 190 μM as previously described
by Monteleone et al [7].
In clinical practice, interpretation of an individual PAA value is compromised by the fact
that concentrations vary considerably over the course of the day due to the relatively short
half-lives of PBA and PAA. For example among the clinical trials comprising the present
analyses, plasma PAA fluctuation index varied from 843% - 3931%; and fasting and
maximal PAA levels in HE patients ranged from 0 - 1.3 μg/mL and 248 - 532 μg/mL,
respectively. As compared with measurement of PAA alone, measurement of the
PAA:PAGN ratio appears to be a useful proxy for the efficiency with which an individual
patient converts PAA to PAGN, and a predictor of patients at risk of having an elevated
PAA level. The PAA:PAGN ratio also has an important clinical advantage in that it remains
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comparatively constant over the day and, therefore, is more readily interpretable in a random
blood draw.
These analyses have several limitations. First, although pharmacokinetic and safety data
were derived from controlled prospective studies, the analyses of the frequency of the
specific AEs reported by Thibault et al. [35], [36] were done as post hoc analysis. Second,
PAA levels were not always available at precisely the time of occurrence of neurological
AEs, though a conservative approach was taken in these analyses by utilizing the highest
recorded PAA for that dosing period. Finally, these conclusions pertaining to the absence of
a statistical relationship between plasma PAA levels and neurological AEs apply at the
population levels and may not apply to individual UCD or HE patients [38]. Since the
symptoms reportedly associated with elevated PAA levels are non-specific and similar to
those associated with elevated ammonia, it is possible that PAA may occasionally cause
reversible AEs that go clinically unrecognized or are attributed to something else.
Collectively, the present findings indicate that the PAA:PAGN ratio is a useful dosing
biomarker suitable for use with random blood draws and they suggest further that dose
reduction may be warranted in patients receiving PAA prodrugs with an elevated plasma
PAA:PAGN ratio who exhibit neurological adverse events not explained by elevated
ammonia or intercurrent illness.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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List of Abbreviations
GEE generalized estimating equations
GPB glycerol phenylbutyrate (generic name for glyceryl tri (4-
phenylbutyrate), also referred to as HPN-100 or RAVICTI®)
HE hepatic encephalopathy
NaPBA sodium phenylbutyrate (BUPHENYL®)
PAA phenylacetic acid
PAA:PAGN ratio ratio of the concentrations in μg/mL of PAA to PAGN in plasma
PAGN phenylacetylglutamine
PBA phenylbutyric acid
SE safety extension
SO switchover
UCD urea cycle disorder
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Highlights
• Plasma PAA levels > 500 ug/dl associated with neurological AE in cancer
patients
• Investigated trend of PAA and neurological AE in patients treated with PAA
pro-drug
• Neurological AEs are transient in patients treated with PAA pro-drug
• High plasma PAA/PAGN identified patients at risk for high PAA levels
• No correlation was found in patients between PAA levels and neurological AEs
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Figure 1. Lack of Relationship Between PAA Levels and Neurological AEs in UCD and HE
Patients
The top and middle panels depict box-and-whisker plots for the mean maximal (Cmax)
concentration of PAA during dosing of UCD patients with sodium phenylbutyrate and
glycerol phenylbutyrate, respectively. There was no statistical difference in maximal PAA
levels between UCD patients who did or did not report neurological AEs. The bottom panel
depicts mean PAA concentrations (mean [SD] = 61.4 [75.3] vs. 36.4 [55.6]; p = 0.77)
among patients with cirrhosis and hepatic encephalopathy randomized to treatment with
glycerol phenylbutyrate who reported neurological adverse events. The range of PAA
concentrations as reflected by the box (25th to 75th percentile) are similar for patients who
did or did not report an AE. The dots depict individual values. (See Table 2 for statistical
summary)
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Figure 2. PAA Levels in Healthy Adults Reporting a Nervous System Adverse Event (AE)
Grouped by Dose
The maximum PAA value (Cmax) is displayed in relation to dose of glycerol phenylbutyrate
for patients who did or did not report a neurological adverse event (AE), regardless of
relationship to study drug or timing relative to blood draw for PAA. The box and whisker
plots depict mean (horizontal line), 25-75 percentiles (box) and 10 and 90% confidence
intervals. Note that a wide range of PAA levels was observed at each dose and among
patients with or without AEs. PAA levels were significantly higher among patients with AEs
as compared to those without at the 6mL TID dose, but not at the 4 mL TID dose. All but 1
subject in the 9 and 12 mL dose groups reported a neurological AE. (See Table 2 for
statistical summary)
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Figure 3. Plasma PAA Intra-subject Variability
Healthy subjects and patients with UCD or HE underwent serial blood sampling over 12 to
24 hours. The figure depicts the coefficient of variation (CV%) as an indicator of intra-
subject variability. Regardless of the dose or population, there is high degree of variability
among all subjects.
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Figure 4. Plasma PAA vs. Plasma PAA:PAGN Ratio
PAA levels in μg/mL (Y axis) are plotted in relation to the ratio of PAA to PAGN
concentration (both expressed as μgμg/mL) in plasma (X axis) in that same sample. This plot
includes >3500 samples from all populations, including healthy adults (Healthy), patients
with cirrhosis and hepatic encephalopathy (Hepatic), and patients with urea cycle disorders
(UCD). All populations exhibit a similar relationship, with the upward inflection point
occurring at ratios exceeding approximately 2.5 and PAA concentrations in the range of
100-200 μg/ml.
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Table 1
Clinical Studies and Subject Disposition
Populations Study ID, Design and Objectives Ages / No. Treated Study Drug / Duration
Healthy Adult Volunteers HPN-100-010
Thorough QT/QTc study
Arm 1: safety run-in
Arm 2: double-blind, randomized,crossover
Adults ≥ 18 N:98
Arm 1: 9 mL TID: 12
12 mL TID: 4
Arm 2: 4 mL TID: 68
6 mL TID: 68
GPB
3 days
UCD Patients UP 1204-003
Phase 2, open-label, fixed-sequence, switch-
over study
Adults ≥ 18
N:10
Open label, fixed
sequence, NaPBA to GPB
switchover 7 days on each
drug
HPN-100-006
Phase 3, randomized, double-blind,crossover,
active-controlled, multiple-dose study
Adults ≥ 18
N: 44
GPB and NaPBA14 days
randomized, double blind,
double dummy cross over
HPN-100-005SO
Phase 2, open-label, fixed-sequence, switch-
over, multiple-dose study with 12-month safety
extension
Pediatric, patients ages 6-17
N:11
Open label, fixed
sequence, NaPBA to GPB
switchover ≤7 days on
each drug
HPN-100-012SO
Phase 3b, open-label, fixed-sequence, switch-
over study
Pediatric, patients ages 2
months to < 6 yrs
N:15
Open label, fixed
sequence, NaPBA to GPB
switchover ≤7 days on
each drug
HPN-100-005SE
Phase 2, open-label 12-month safety-extension
study
Pediatric ages 6 – 17 years
N: 17
GPB
12 months
HPN-100-012SE
Phase 2, open-label 12-month safety-extension
study
Pediatric ages 29 days to <6
years
N: 23
GPB
12 months
HPN-100-007
Phase 3, open-label, , 12-month safety-
extension study
Adult and pediatric ages ≥ 6
N: 60 (51 adults, 9 pediatric
patients)
GPB
12 months
HE Patients HPN-100-008 (Part A) Open label, safety
and dose-escalation study
Adults ≥ 18
N: 15
GPB
4 weeks
HPN-100-008*
Randomized, double-blind, placebo-controlled
phase 2 study
Adults ≥ 18
N: 178
GPB
16 weeks
GPB – glycerol phenylbutyrate; HE – hepatic encephalopathy; NaPBA – sodium phenylbutyrate; SE – safety extension; SO – switchover; UCD –
urea cycle disorders.
*Used for analysis of PAA levels in relation to AEs only.
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Table 3
Predictive Value of Plasma PAA:PAGN Ratio
Plasma PAA Plasma PAA:PAGN Ratio Probability of a Plasma PAA Value > 400 or 500 μg/mL
≥400 μg/mL ≤ 2.5 0.8%
> 2.5 19.1%
>500 μg/mL ≤ 25 0.3%
>2.5 8.4%
PAA – phenylacetic acid; PAGN – phenylacetylglutamine; PAA:PAGN ratio – ratio of the concentrations of PAA to PAGN in plasma, both in
(μg/mL
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